Dicot's toxicology program successfully completed
Press release: Uppsala, April 27, 2023. Dicot announces today that the preclinical toxicology program required to start clinical phase 1 trial is completed. LIB-01 has shown a good safety profile in the toxicity studies.
Dicot is developing a novel potency drug that aims to become the first choice of treatment for erectile dysfunction and premature ejaculation. The company plans to start clinical studies with the drug candidate LIB-01 in mid-2023.
Today the company announces that the preclinical toxicology program required for clinical phase 1 with LIB-01 has been completed. LIB-01 has shown a good safety profile in the toxicity studies. In accordance with regulations, studies supporting both single dose and repeated dosing in the clinical trial have been conducted in two animal species. The studies have been performed according to Good Laboratory Practice.
Studies of a drug candidate's toxicity constitute a necessary and important part of the safety assessment before the start of clinical studies and are part of the documentation that must be assessed and approved by the authorities before start of clinical trials.
"The successful completion of the toxicology program is a great progress towards the start of our clinical studies and the fact that LIB-01 demonstrates a good safety profile in the program is of course very gratifying," comments Elin Trampe, CEO at Dicot.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.
This disclosure contains information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-04-2023 11:00 CET.
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.